Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis

Vanesa Andreu, Ane Larrea, Pablo Rodriguez-Fernandez, Salvador Alfaro, Begonã Gracia, Ainhoa Luciá, Laura Usón, Andromeda Celeste Gomez, Gracia Mendoza, Alicia Lacoma, Jose Dominguez, Cristina Prat, Victor Sebastian, José Antonio Ainsa, Manuel Arruebo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

© 2019 Future Medicine Ltd. Aim: Production of Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles (NP) against Mycobacterium tuberculosis. Materials & methods: The emulsification and evaporation methods were followed for the synthesis of PLGA-NPs and methacrylic acid-ethyl acrylate-based coatings to protect rifampicin from degradation under simulated gastric conditions. Results & conclusion: The inner antibiotic-loaded NPs here reported can be released under simulated intestinal conditions whereas their coating protects them from degradation under simulated gastric conditions. The encapsulation does not hinder the antituberculosis action of the encapsulated antibiotic rifampicin. A sustained antibiotic release could be obtained when using the drug-loaded encapsulated NPs. Compared with the administration of the free drug, a more effective elimination of M. tuberculosis was observed when applying the NPs against infected macrophages. The antibiotic-loaded PLGA-NPs were also able to cross an in vitro model of intestinal barrier. Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid nanoparticles against M. tuberculosis were produced to protect the antibiotic from degradation under simulated gastric conditions. The antibiotic-loaded poly lactic-co-glycolic acid nanoparticles were able to cross an in vitro model of intestinal barrier, being more effective in the elimination of M. tuberculosis when applied against infected macrophages compared with the use of the free drug. </inline-graphic.
Original languageAmerican English
Pages (from-to)707-726
Number of pages634
JournalNanomedicine
DOIs
StatePublished - 1 Mar 2019
Externally publishedYes

Fingerprint

Antibiotics
Mycobacterium tuberculosis
Anti-Bacterial Agents
Acids
Nanoparticles
Stomach
Macrophages
Rifampin
Degradation
Pharmaceutical Preparations
Coatings
Emulsification
Encapsulation
Medicine
Evaporation
polylactic acid-polyglycolic acid copolymer
Milk

Cite this

Andreu, V., Larrea, A., Rodriguez-Fernandez, P., Alfaro, S., Gracia, B., Luciá, A., ... Arruebo, M. (2019). Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis. Nanomedicine, 707-726. https://doi.org/10.2217/nnm-2018-0258
Andreu, Vanesa ; Larrea, Ane ; Rodriguez-Fernandez, Pablo ; Alfaro, Salvador ; Gracia, Begonã ; Luciá, Ainhoa ; Usón, Laura ; Gomez, Andromeda Celeste ; Mendoza, Gracia ; Lacoma, Alicia ; Dominguez, Jose ; Prat, Cristina ; Sebastian, Victor ; Ainsa, José Antonio ; Arruebo, Manuel. / Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis. In: Nanomedicine. 2019 ; pp. 707-726.
@article{8454a7d0b7bb419699343b19af14855b,
title = "Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis",
abstract = "{\circledC} 2019 Future Medicine Ltd. Aim: Production of Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles (NP) against Mycobacterium tuberculosis. Materials & methods: The emulsification and evaporation methods were followed for the synthesis of PLGA-NPs and methacrylic acid-ethyl acrylate-based coatings to protect rifampicin from degradation under simulated gastric conditions. Results & conclusion: The inner antibiotic-loaded NPs here reported can be released under simulated intestinal conditions whereas their coating protects them from degradation under simulated gastric conditions. The encapsulation does not hinder the antituberculosis action of the encapsulated antibiotic rifampicin. A sustained antibiotic release could be obtained when using the drug-loaded encapsulated NPs. Compared with the administration of the free drug, a more effective elimination of M. tuberculosis was observed when applying the NPs against infected macrophages. The antibiotic-loaded PLGA-NPs were also able to cross an in vitro model of intestinal barrier. Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid nanoparticles against M. tuberculosis were produced to protect the antibiotic from degradation under simulated gastric conditions. The antibiotic-loaded poly lactic-co-glycolic acid nanoparticles were able to cross an in vitro model of intestinal barrier, being more effective in the elimination of M. tuberculosis when applied against infected macrophages compared with the use of the free drug. </inline-graphic.",
author = "Vanesa Andreu and Ane Larrea and Pablo Rodriguez-Fernandez and Salvador Alfaro and Begon{\~a} Gracia and Ainhoa Luci{\'a} and Laura Us{\'o}n and Gomez, {Andromeda Celeste} and Gracia Mendoza and Alicia Lacoma and Jose Dominguez and Cristina Prat and Victor Sebastian and Ainsa, {Jos{\'e} Antonio} and Manuel Arruebo",
year = "2019",
month = "3",
day = "1",
doi = "10.2217/nnm-2018-0258",
language = "American English",
pages = "707--726",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",

}

Andreu, V, Larrea, A, Rodriguez-Fernandez, P, Alfaro, S, Gracia, B, Luciá, A, Usón, L, Gomez, AC, Mendoza, G, Lacoma, A, Dominguez, J, Prat, C, Sebastian, V, Ainsa, JA & Arruebo, M 2019, 'Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis', Nanomedicine, pp. 707-726. https://doi.org/10.2217/nnm-2018-0258

Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis. / Andreu, Vanesa; Larrea, Ane; Rodriguez-Fernandez, Pablo; Alfaro, Salvador; Gracia, Begonã; Luciá, Ainhoa; Usón, Laura; Gomez, Andromeda Celeste; Mendoza, Gracia; Lacoma, Alicia; Dominguez, Jose; Prat, Cristina; Sebastian, Victor; Ainsa, José Antonio; Arruebo, Manuel.

In: Nanomedicine, 01.03.2019, p. 707-726.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis

AU - Andreu, Vanesa

AU - Larrea, Ane

AU - Rodriguez-Fernandez, Pablo

AU - Alfaro, Salvador

AU - Gracia, Begonã

AU - Luciá, Ainhoa

AU - Usón, Laura

AU - Gomez, Andromeda Celeste

AU - Mendoza, Gracia

AU - Lacoma, Alicia

AU - Dominguez, Jose

AU - Prat, Cristina

AU - Sebastian, Victor

AU - Ainsa, José Antonio

AU - Arruebo, Manuel

PY - 2019/3/1

Y1 - 2019/3/1

N2 - © 2019 Future Medicine Ltd. Aim: Production of Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles (NP) against Mycobacterium tuberculosis. Materials & methods: The emulsification and evaporation methods were followed for the synthesis of PLGA-NPs and methacrylic acid-ethyl acrylate-based coatings to protect rifampicin from degradation under simulated gastric conditions. Results & conclusion: The inner antibiotic-loaded NPs here reported can be released under simulated intestinal conditions whereas their coating protects them from degradation under simulated gastric conditions. The encapsulation does not hinder the antituberculosis action of the encapsulated antibiotic rifampicin. A sustained antibiotic release could be obtained when using the drug-loaded encapsulated NPs. Compared with the administration of the free drug, a more effective elimination of M. tuberculosis was observed when applying the NPs against infected macrophages. The antibiotic-loaded PLGA-NPs were also able to cross an in vitro model of intestinal barrier. Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid nanoparticles against M. tuberculosis were produced to protect the antibiotic from degradation under simulated gastric conditions. The antibiotic-loaded poly lactic-co-glycolic acid nanoparticles were able to cross an in vitro model of intestinal barrier, being more effective in the elimination of M. tuberculosis when applied against infected macrophages compared with the use of the free drug. </inline-graphic.

AB - © 2019 Future Medicine Ltd. Aim: Production of Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles (NP) against Mycobacterium tuberculosis. Materials & methods: The emulsification and evaporation methods were followed for the synthesis of PLGA-NPs and methacrylic acid-ethyl acrylate-based coatings to protect rifampicin from degradation under simulated gastric conditions. Results & conclusion: The inner antibiotic-loaded NPs here reported can be released under simulated intestinal conditions whereas their coating protects them from degradation under simulated gastric conditions. The encapsulation does not hinder the antituberculosis action of the encapsulated antibiotic rifampicin. A sustained antibiotic release could be obtained when using the drug-loaded encapsulated NPs. Compared with the administration of the free drug, a more effective elimination of M. tuberculosis was observed when applying the NPs against infected macrophages. The antibiotic-loaded PLGA-NPs were also able to cross an in vitro model of intestinal barrier. Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid nanoparticles against M. tuberculosis were produced to protect the antibiotic from degradation under simulated gastric conditions. The antibiotic-loaded poly lactic-co-glycolic acid nanoparticles were able to cross an in vitro model of intestinal barrier, being more effective in the elimination of M. tuberculosis when applied against infected macrophages compared with the use of the free drug. </inline-graphic.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063108422&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85063108422&origin=inward

U2 - 10.2217/nnm-2018-0258

DO - 10.2217/nnm-2018-0258

M3 - Article

C2 - 30734643

SP - 707

EP - 726

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

ER -